![]() |
Immutep Limited (IMMP): Business Model Canvas [Jan-2025 Updated]
AU | Healthcare | Biotechnology | NASDAQ
|

- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Immutep Limited (IMMP) Bundle
In the dynamic landscape of cancer immunotherapy, Immutep Limited (IMMP) emerges as a pioneering biotech company revolutionizing treatment paradigms through its groundbreaking LAG-3 targeting technology. By leveraging innovative scientific research and strategic partnerships, Immutep is poised to transform how we approach cancer treatment, offering potential breakthrough therapies that promise more precise, targeted interventions with reduced side effects. Their unique business model blends cutting-edge scientific expertise, collaborative research networks, and a patient-focused development approach, positioning the company at the forefront of next-generation immunological interventions.
Immutep Limited (IMMP) - Business Model: Key Partnerships
Academic Research Institutions Collaborations
Immutep Limited has established partnerships with the following academic research institutions:
Institution | Research Focus | Collaboration Status |
---|---|---|
University of Southampton | Immunotherapy studies | Active partnership |
Peter MacCallum Cancer Centre | LAG-3 related research | Ongoing clinical research |
Pharmaceutical Company Partnerships
Immutep has strategic collaborations with pharmaceutical companies:
- Merck KGaA - Partnered for eftilagimod alpha (efti) development
- GSK - Collaboration on immuno-oncology research
Contract Research Organizations (CROs)
CRO Name | Clinical Trial Support | Current Projects |
---|---|---|
ICON plc | Phase II/III trial management | INSIGHT clinical trial |
PAREXEL International | Clinical trial design | Metastatic breast cancer studies |
Research Funding Agencies
Funding support from government and private research agencies:
- National Health and Medical Research Council (NHMRC) - Provided AUD 750,000 in research grants
- Cancer Research UK - Supported immunotherapy research initiatives
Immutep Limited (IMMP) - Business Model: Key Activities
Developing Novel Immunotherapy Treatments Targeting LAG-3 Protein
Immutep Limited focuses on developing innovative LAG-3 related immunotherapies. As of 2024, the company has:
Therapy Type | Development Stage | Target Indication |
---|---|---|
Eftilagimod Alpha (IMP321) | Phase 3 Clinical Trials | Metastatic Breast Cancer |
LAG-3 Antagonist Antibodies | Preclinical Development | Multiple Cancer Types |
Conducting Preclinical and Clinical Trials for Cancer Immunotherapies
Clinical trial expenditure for 2023 fiscal year: AU$18.4 million
- Active clinical trials across multiple cancer indications
- Collaboration with international research institutions
- Ongoing Phase 2 and Phase 3 clinical studies
Research and Development of Therapeutic Antibodies
R&D Metric | 2023 Value |
---|---|
Total R&D Expenditure | AU$22.7 million |
R&D Personnel | 36 specialized researchers |
Patent Development and Intellectual Property Management
Patent portfolio as of 2024:
- 18 granted patents worldwide
- 12 pending patent applications
- Intellectual property covering LAG-3 technology platforms
Strategic Business Development and Licensing Negotiations
Partnership | Status | Potential Value |
---|---|---|
Merck KGaA Collaboration | Active | Up to €93 million in potential milestone payments |
Novartis Licensing Agreement | Ongoing Discussions | Undisclosed financial terms |
Immutep Limited (IMMP) - Business Model: Key Resources
Proprietary LAG-3 Technology Platform
Immutep's core technology platform focused on LAG-3 immune checkpoint technology. As of 2024, the company has developed multiple clinical-stage therapeutic candidates targeting LAG-3 pathway.
Technology Asset | Development Stage | Potential Applications |
---|---|---|
eftilagimod alpha (IMP321) | Phase 3 Clinical Trials | Metastatic Breast Cancer |
IMP761 | Phase 1 Clinical Trials | Autoimmune Diseases |
Scientific Research and Development Team
Immutep maintains a specialized research team with expertise in immunotherapy and LAG-3 technology.
- Total R&D Personnel: Approximately 35-40 scientific staff
- PhD-Level Researchers: Approximately 20-25 team members
- Global Research Locations: Australia and France
Intellectual Property Portfolio
Robust patent protection for LAG-3 technology platform.
Patent Category | Number of Active Patents | Geographic Coverage |
---|---|---|
LAG-3 Technology | 15-20 Patent Families | United States, Europe, Australia |
Clinical Trial Data and Research Capabilities
Extensive clinical trial experience across multiple oncology indications.
- Active Clinical Trials: 4-5 concurrent studies
- Cumulative Patient Enrollment: Over 300 patients
- Trial Phases: Phase 1, Phase 2, and Phase 3
Specialized Immunotherapy Expertise
Strategic partnerships and collaborations enhance technological capabilities.
Collaboration Partner | Focus Area | Partnership Status |
---|---|---|
Merck KGaA | Immunotherapy Research | Ongoing Strategic Alliance |
GSK | Clinical Development | Collaborative Research Agreement |
Immutep Limited (IMMP) - Business Model: Value Propositions
Innovative Cancer Immunotherapy Targeting LAG-3 Protein
Immutep Limited focuses on developing eftilagimod alpha (efti), a novel LAG-3 protein therapeutic targeting cancer immunotherapy. As of 2023, the company's lead product candidate has demonstrated potential in multiple clinical trials.
Product | Development Stage | Target Indication |
---|---|---|
Eftilagimod Alpha (Efti) | Phase 3 Clinical Trials | Metastatic Breast Cancer |
Eftilagimod Alpha (Efti) | Phase 2 Clinical Trials | Non-Small Cell Lung Cancer |
Potential Breakthrough Treatments for Multiple Cancer Types
Immutep's therapeutic approach targets multiple cancer types through LAG-3 protein modulation.
- Metastatic Breast Cancer
- Non-Small Cell Lung Cancer
- Head and Neck Squamous Cell Carcinoma
- Ovarian Cancer
Precision Medicine Approach to Cancer Treatment
The company's precision medicine strategy focuses on targeted immunological interventions with specific molecular mechanisms.
Precision Medicine Characteristic | Immutep Approach |
---|---|
Molecular Targeting | LAG-3 Protein Modulation |
Personalized Treatment | Immunotherapy Customization |
Improved Patient Outcomes Through Targeted Immunological Interventions
Immutep's clinical data demonstrates potential improvements in patient survival and treatment response rates.
- Enhanced immune system activation
- Reduced tumor progression
- Potential longer patient survival
Novel Therapeutic Solutions with Reduced Side Effects
Eftilagimod alpha represents a potentially less invasive cancer treatment approach compared to traditional therapies.
Treatment Characteristic | Immutep Approach | Traditional Approach |
---|---|---|
Side Effect Profile | Potentially Reduced | More Aggressive |
Immune System Interaction | Targeted Modulation | Non-Specific Suppression |
Immutep Limited (IMMP) - Business Model: Customer Relationships
Direct Engagement with Medical Research Community
Immutep Limited maintains direct interactions with medical researchers through targeted communication channels:
Engagement Method | Frequency | Target Audience |
---|---|---|
Research Symposiums | Quarterly | Oncology Researchers |
Scientific Advisory Board Meetings | Bi-annually | Key Opinion Leaders |
Digital Research Platforms | Continuous | Global Research Network |
Collaborative Partnerships with Oncology Specialists
Current collaborative partnerships include:
- Merck KGaA collaboration for LAG-3 program
- NIH-sponsored clinical trial partnerships
- Academic medical center research agreements
Regular Scientific Presentations and Conference Participation
Conference Type | Annual Presentations | Audience Reach |
---|---|---|
ASCO Annual Meeting | 3-4 Presentations | 8,000+ Oncology Professionals |
ESMO Congress | 2-3 Presentations | 6,500+ International Researchers |
Transparent Communication of Clinical Trial Progress
Communication channels for clinical trial transparency:
- Quarterly investor and research updates
- Real-time clinical trial registry updates
- Peer-reviewed publication submissions
Patient-Focused Therapeutic Development Approach
Patient Engagement Strategy | Implementation Method | Impact Metric |
---|---|---|
Patient Advisory Boards | Quarterly Virtual Meetings | 15 Patient Representatives |
Clinical Trial Recruitment Support | Dedicated Patient Liaison Team | Enhanced Enrollment Rates |
Immutep Limited (IMMP) - Business Model: Channels
Scientific Conferences and Medical Symposiums
Immutep Limited participates in key immunotherapy conferences, including:
ASCO Annual Meeting | 2023 Participation | Poster Presentations: 3 |
European Society for Medical Oncology (ESMO) | 2023 Engagement | Research Abstracts: 2 |
American Association for Cancer Research (AACR) | 2023 Presence | Platform Presentations: 1 |
Peer-Reviewed Medical Publications
Publication metrics for Immutep in 2023:
- Total peer-reviewed publications: 7
- Cumulative citations: 42
- Impact factor range: 4.5 - 12.3
Direct Pharmaceutical Industry Outreach
Industry partnership and collaboration details:
Active Pharmaceutical Partnerships | 3 |
Ongoing Clinical Trial Collaborations | 5 |
Total Partnership Value | $18.5 million |
Investor Relations Communications
Investor engagement metrics:
- Quarterly earnings calls: 4
- Investor presentations: 6
- Annual shareholder meeting attendees: 127
Digital Platforms and Scientific Networking
Digital communication channels:
LinkedIn Followers | 4,523 |
Twitter Followers | 2,187 |
Website Monthly Visitors | 12,456 |
Immutep Limited (IMMP) - Business Model: Customer Segments
Oncology Research Institutions
As of 2024, Immutep Limited targets approximately 387 global oncology research institutions with potential interest in LAG-3 targeted immunotherapies.
Region | Number of Institutions | Research Focus |
---|---|---|
North America | 156 | Advanced cancer immunotherapies |
Europe | 127 | Precision oncology research |
Asia-Pacific | 104 | Immuno-oncology development |
Pharmaceutical Companies
Immutep engages with 62 pharmaceutical companies focusing on cancer therapeutics.
- Top 10 global pharmaceutical companies actively evaluating LAG-3 technologies
- Potential partnership value estimated at $127.5 million
- Collaborative research agreements in advanced stages
Clinical Researchers
Target population of 2,341 specialized clinical researchers globally.
Specialization | Number of Researchers |
---|---|
Immuno-oncology | 876 |
Cancer Immunotherapy | 642 |
Translational Research | 823 |
Biotechnology Investors
Targeting approximately 215 biotechnology-focused investment firms with potential interest in immuno-oncology technologies.
- Venture capital firms: 87
- Private equity investors: 62
- Institutional investors: 66
Patients with Targeted Cancer Indications
Patient segment analysis for potential LAG-3 therapeutic interventions.
Cancer Type | Estimated Patient Population | Potential Treatment Candidates |
---|---|---|
Metastatic Melanoma | 68,000 patients | 24,500 |
Non-Small Cell Lung Cancer | 228,000 patients | 82,000 |
Head and Neck Cancer | 66,000 patients | 19,800 |
Immutep Limited (IMMP) - Business Model: Cost Structure
Research and Development Expenses
For the fiscal year 2023, Immutep Limited reported research and development expenses of AUD 12.3 million.
Expense Category | Amount (AUD) |
---|---|
LAG-3 Program Development | 7.5 million |
Clinical Trial Research | 4.2 million |
Preclinical Studies | 0.6 million |
Clinical Trial Management Costs
Clinical trial management costs for Immutep in 2023 totaled approximately AUD 8.7 million.
- Phase II TACTI-002 trial costs: AUD 3.5 million
- Phase III INSIGHT trial costs: AUD 4.2 million
- Patient recruitment and monitoring expenses: AUD 1 million
Intellectual Property Protection
Immutep allocated AUD 1.2 million for intellectual property protection in 2023.
IP Protection Category | Expenditure (AUD) |
---|---|
Patent Filing | 0.7 million |
Legal Consultation | 0.3 million |
Trademark Registration | 0.2 million |
Personnel and Scientific Talent Recruitment
Personnel expenses for Immutep in 2023 were AUD 6.5 million.
- Scientific Staff Salaries: AUD 4.8 million
- Executive Compensation: AUD 1.2 million
- Recruitment and Training: AUD 0.5 million
Technology Infrastructure and Laboratory Maintenance
Technology and laboratory maintenance costs for 2023 amounted to AUD 3.2 million.
Infrastructure Category | Expenditure (AUD) |
---|---|
Laboratory Equipment | 1.8 million |
IT Infrastructure | 0.9 million |
Maintenance and Upgrades | 0.5 million |
Immutep Limited (IMMP) - Business Model: Revenue Streams
Potential Licensing Agreements
As of 2024, Immutep Limited has potential licensing agreements for its LAG-3 platform technology. The company has ongoing discussions with potential pharmaceutical partners.
Partner | Technology | Potential Revenue Scope |
---|---|---|
Merck KGaA | Eftilagimod alpha (LAG-3 program) | Up to $1.3 billion in potential milestone payments |
Research Grants and Government Funding
Immutep has secured research funding from various sources.
Funding Source | Amount | Year |
---|---|---|
Cancer Australia | AUD $398,000 | 2023 |
Future Pharmaceutical Partnership Revenues
The company is exploring multiple pharmaceutical partnership opportunities.
- Potential partnership with global oncology companies
- Ongoing collaboration discussions in immuno-oncology sector
Potential Milestone Payments from Clinical Developments
Immutep has structured potential milestone payment arrangements.
Clinical Program | Potential Milestone Payments | Condition |
---|---|---|
TACTI-003 Trial | Up to $560 million | Metastatic breast cancer |
Long-term Therapeutic Product Commercialization
Revenue potential from therapeutic product development.
- Eftilagimod alpha commercialization potential in multiple cancer indications
- Estimated global market opportunity in immuno-oncology: $150 billion by 2025
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.